BioRay Pharmaceutical Co., Ltd.
Clinical trials sponsored by BioRay Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New gout pill BR2251 enters Mid-Stage trial Results expected Oct 2026 (estimated)
- New antibody drug aims to tackle kidney disease Results expected Mar 2027 (estimated)
-
New antibody drug zuberitamab takes aim at kidney disease in phase 3 trial
Disease control Not yet recruitingResearchers are testing an experimental antibody drug called zuberitamab in people with primary membranous nephropathy, a kidney condition that causes protein to leak into the urine. The trial compares zuberitamab injections with cyclosporine, a standard immune-suppressing drug, …
Phase 3 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 22, 2026 02:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New gout pill BR2251 enters Mid-Stage trial
Disease control Not yet recruitingThis Phase 2 trial tests BR2251, a new daily tablet, in 160 adults with gout and high uric acid. Participants receive one of three doses of BR2251 or the standard drug febuxostat for 12 weeks. The goal is to see which dose best lowers uric acid levels and reduces gout flare-ups.
Phase 2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New targeted drug shows promise for Hard-to-Treat gynecologic cancers
Disease control Not yet recruitingThis study tests a new drug called BRY812 in people with advanced ovarian, endometrial, or ovarian clear cell cancers that have a specific marker (LIV-1). The goal is to see if the drug can shrink tumors and how safe it is. About 56 participants will receive the drug, and researc…
Phase 2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC